Markets recouped early losses and were trading flat as gains in export-led sectors suchs as information technology and pharma helped offset most of the losses in FMCG and select financials. However, the sharp sell-off in Chinese shares continued to weigh on market sentiment.
At 10:35AM, the 30-share Sensex was down 2 points at 27,830 and the 50-share Nifty was down 3 points at 8,463.
In the broader market the BSE Mid-cap and Small-cap indices were up 0.2-0.4% each. Market breadth was positive with 845 gainers and 603 losers in early trade.
"For the Sensex resistance is at 27897 above 27994 and 28038. Support is at 27707 below 27638. In case of NIFTY resistance is at 8485 above 8515. Support is at 8440, 8432, 8428 below 8400," Geojit BNP Paribas said in a note.
Meanwhile, the rupee continued to trade weak against the US dollar. The rupee was trading lower by 5 paise at 65.36 compared to its previous close on Monday.
Foreign institutional investors were net sellers in equities to the tune of Rs 255 crore on Tuesday, as per provisional stock exchange data.
BSE Healthcare, Consumer Durables, Oil and Gas indices were the top gainers while Metal and Bankex indices were the top losers.
Export-led stocks in the IT and pharma space gained on expectations that the weakening rupee would help boost revenues during the second quarter. Sun Pharma was the top gainer up 2.6% followed by Lupin, Cipla and Dr Reddy's Labs.
Among IT exporters, Infosys, TCS and Wipro were up 0.1-0.9% each.
Metal shares were down tracking amid concerns of weak demand from China. Tata Steel and Hindalco were down 0.3-1% each.
FMCG shares witnessed profit taking amid concerns that weak monsoon would hurt rural volume growth. ITC eased 0.6% while HUL was trading flat.
Other Sensex losers include, HDFC, HDFC Bank and Bharti Airtel among others.
Among other shares, Glenmark Pharmaceuticals hit a new high of Rs 1,187 on the Bombay Stock Exchange (BSE) in early morning trades after the company said it has received final approval from the US drug regulator for drospirenone and ethinyl estradiol tablets.
Shares of Majesco are locked at the upper circuit, up 5% at Rs 332, on the National Stock Exchange (NSE) on its first day of listing pursuant to the demerger of the insurance products and services business of Mastek into the company.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)